Vectura’s board of directors intend to unanimously recommend tobacco giant Philip Morris International’s £1.65 ($2.28) per share cash takeover offer, snubbing private equity Carlyle’s lower scheme of arrangement proposal, after recognizing “the superior cash price the final Philip Morris offer provides Vectura shareholders.”
Vectura Opts For Tobacco Giant Philip Morris In Carlyle Takeover Tussle
‘Superior Cash Offer’ Worth £1.1bn Proves Decisive
Vectura’s board of directors has chosen cigarette manufacturer Philip Morris’ superior cash offer, turning down US private equity Carlyle, following a months-long battle between the two bidders for the inhalation specialist that was set to go to a rare auction in the UK.

More from Deals
The move adds another compound with the coveted 180-day exclusivity to Hikma’s portfolio for an undisclosed sum.
After announcing the agreement last month, Xbrane has now approved its deal with Alvotech as part of an extra general meeting.
With six biosimilars reportedly in development, Polpharma Biologics has linked up with Chinese CDMO Chime Biologics, looking to tap its “all-in-one solutions to accelerate biosimilar development and reduce the time-to-market” for an undisclosed biosimilar product.
The divestment marks a further step in Fresenius’ ongoing strategy towards a more optimized and simplified company structure while doubling down on new endeavors in the Biopharma space.
More from Business
With six biosimilars reportedly in development, Polpharma Biologics has linked up with Chinese CDMO Chime Biologics, looking to tap its “all-in-one solutions to accelerate biosimilar development and reduce the time-to-market” for an undisclosed biosimilar product.
The divestment marks a further step in Fresenius’ ongoing strategy towards a more optimized and simplified company structure while doubling down on new endeavors in the Biopharma space.
Aurobindo is set to join Lupin by competing against Johnson/Bayer’s blockbuster blood thinner Xarelto (rivaroxaban) 2.5mg tablets.